retatrutide targets 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Demand for Unapproved Weight-Loss Drug

This interplay suggests that care structures might benefit from redesign: interdisciplinary teams including nutritionists, psychologists, primary care providers, and social support systems should be considered early in the treatment process to better support behavior change alongside pharmacotherapy

Frontiers in Oncology 10

The drug that produces greater total weight loss will also produce greater absolute lean mass loss

This regulatory difference is why compounded formulations carry BUDs rather than expiration dates, and why those BUDs tend to be shorter

Changes in blood sugar control If you have diabetes, you might notice: More stable blood sugar readings Lower fasting blood sugar levels Potentially a drop in your A1C beyond what semaglutide achieved For someone with an A1C of about 7% on semaglutide, tirzepatide might bring it closer to your target goal

Users suggest focusing on smaller, protein-rich meals to stay full without overwhelming your digestive system